Fennec Pharmaceuticals Inc (FENC): Narxning daromadga nisbati

Fennec (FENC) tovar belgisi

Sinov ma'lumotlarini qayta ishlash uchun dasturiy robotlarning joriy etilishi Fennec Pharmaceuticals (FENC) jarayonlarini optimallashtiradi, bu esa narxlar dinamikasida aks etgan. Sotuvlar nisbatidagi narx koeffitsiyenti 5.80 ko'rsatkichning yangi qiymatiga aylangan joriy tendentsiyani namoyish etmoqda. Pedmark mahsulotining monopoliya holati yuqori marja va pul oqimini kafolatlaydi, bolalar eshitish qobiliyatini himoya qilishga qaratilgan e'tibor esa ushbu hayotiy muhim davolash usuli uchun barqaror bozor nishasini yaratadi.

FENC Fennec Pharmaceuticals P/S multiplikatori (09.04.2023 - 13.11.2026)

Fennec Pharmaceuticals Inc (FENC) - koʻrsatkichlar kesimi va moliyaviy hisobotlar

- joriy kotirovkalar va o'rtacha qiymat prognozi:
Birja narxi fennecpharma.com|FENC - Maqsadli narxlar grafigi
- birja kapitallashuvi ma'lumotlari:
Bozor qiymati Fennec Pharmaceuticals Inc|FENC - Kompaniyaning to‘liq qiymati
- emitentning balans qiymati statistikasi:
Bitta aksiya hisobiga sof aktivlar qiymati Fennec Pharmaceuticals|FENC - Balans kapitallashuvi|Bozor qiymatining xususiy kapitalga nisbati fennecpharma.com|FENC - Kompaniyaning yakuniy aktivlari
- emitentning kredit yuki va likvidlik ko'rsatkichlari:
Qarzning kapitalga nisbati Fennec Pharmaceuticals|FENC - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzdorlikning kapitalga nisbati Fennec|FENC - Kompaniyaning umumiy qarzi|Qarzning balans kapitaliga nisbati Fennec Pharmaceuticals Inc|FENC - Kompaniyaning uzoq muddatli qarzlari|Kompaniyaning qisqa muddatli kredit va qarzlari Fennec Pharmaceuticals|Shoshilinch likvidlik fennecpharma.com
- foyda va multiplikatorlar bo'yicha ma'lumotlar:
FENC - Kompaniyaning sof foydasi|Kutilayotgan sof daromad Fennec Pharmaceuticals|FENC - P/E multiplikatori|Forvard P/E multiplikatori Fennec Pharma|FENC - Narxning foydaga va o‘sish sur’atiga nisbati|Kompaniya qiymatining amortizatsiyadan oldingi operatsion foydaga nisbati Fennec Pharmaceuticals Inc|FENC - Eskirish chegirilmasdan oldingi operatsion foyda|So'nggi o'n ikki oy davomida bitta aksiya uchun sof foyda Fennec Pharmaceuticals|FENC - Bir aksiya uchun sof foyda (EPS TTM)|So'nggi o'n ikki oy davomida bir aksiya uchun sof foydaning yillik dinamikasi fennecpharma.com|FENC - Joriy yilda foyda o'sishi|Keyingi yilda bir aksiya uchun sof foydaning kutilayotgan o'sishi Fennec Pharmaceuticals
- emitentning tushumi va sotuvlari tafsilotlari:
FENC - Kompaniya daromadi|Kompaniya daromadi prognozi fennecpharma.com|FENC - Narxning daromadga nisbati|Kapitalizatsiyaning prognoz qilingan daromadga nisbati Fennec Pharmaceuticals Inc
Kompaniyaning jamlanma tahliliyoti:fennecpharma.com
Fennec seriyali mahsuloti

Koeffitsient operatsion ko'rsatkichlar o'zgarishi bilan birga, investorlarning sotuvlarning har bir birligi uchun qo'shimcha to'lov qilishga tayyorligini aks ettirgan holda, bozor kapitalizatsiyasini yillik daromad bilan bog'laydi. Fennec Pharmaceuticals (FENC) holatida, yuqori baholash uning monopol mavqei va noyob dori vositasining patent himoyasi bilan asoslanadi, bu esa P/S koeffitsientini davolash muqobillarining yo'qligi tufayli berilgan qo'shimcha qiymatni tahlil qilish va grafikdagi risklar muvozanatini vizuallashtirish vositasiga aylantiradi.

Raqobatdosh kompaniyalar

INCY - Sotuvga nisbatan narx|Narxning daromadga nisbati HUTCHMED HCM|Nuvation Bio Inc - Narxning daromadga nisbati|DAWN - Narxning daromadga nisbati|Sotuvga nisbatan narx Monopar Corp|INBX: P/S multiplikatori|Narx/daromad multiplikatori I-Mab Biopharma IMAB|Kapitalizatsiyaning daromadga nisbati HRTX|Sotuvga nisbatan narx Nuvectis Pharma Inc. NVCT|Kapitalizatsiyaning daromadga nisbati CHRS (Coherus)|CRBP (Corbus Pharmaceuticals, Inc.) - Bozor kapitallashuvining daromadga nisbati|Cardiff Oncology - Kapitalizatsiyaning daromadga nisbati|Kapitalizatsiyaning sotish hajmiga nisbati BYSI (beyondspringpharma.com)|BioAtla Corp - P/S multiplikatori|Bozor kapitallashuvining daromadga nisbati LIXT (Lixte Biotechnology Holdings Inc.)|CTXR: P/S multiplikatori|Sotuvga nisbatan narx Cellectar Corp (CLRB)|Narxning daromadga nisbati BioLineRx Ltd.|CANF: Bozor kapitallashuvining daromadga nisbati|P/S multiplikatori APRE|P/S multiplikatori kaziatherapeutics.com (KZIA)|Narxning daromadga nisbati Silexion Therapeutics SLXN|NCNA (NuCana PLC) - Narxning sotuvga nisbati|CMRX: Kapitalizatsiyaning daromadga nisbati|Sotuvga nisbatan narx cyclacel.com|GTHX: P/S multiplikatori|Narxning sotuvga nisbati KRON (Kronos Bio Inc)|KTRA (Kintara) - P/S multiplikatori|Sotuvga nisbatan narx Oncternal Corp ONCT|Narxning daromadga nisbati Portage Biotech Inc. (PRTG)